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Dihydroorotate dehydrogenase (DHODH) is the fourth enzyme in the de novo pyrimidine biosynthetic
pathway and has been exploited as the target for therapy against proliferative and parasitic diseases. In
this study, we report the crystal structures of DHODH from Leishmania major, the species of Leishmania
associated with zoonotic cutaneous leishmaniasis, in its apo form and in complex with orotate and
fumarate molecules. Both orotate and fumarate were found to bind to the same active site and exploit
similar interactions, consistent with a ping-pong mechanism described for class 1A DHODHs. Analysis of
LmDHODH structures reveals that rearrangements in the conformation of the catalytic loop have direct
inﬂuence on the dimeric interface. This is the ﬁrst structural evidence of a relationship between the
dimeric form and the catalytic mechanism. According to our analysis, the high sequence and structural
similarity observed among trypanosomatid DHODH suggest that a single strategy of structure-based
inhibitor design can be used to validate DHODH as a druggable target against multiple neglected trop-
ical diseases such as Leishmaniasis, Sleeping sickness and Chagas’ diseases.
 2012 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
The term “Negleted Tropical Diseases (NTDs)” refers to a large
and complex group of parasitic and bacterial infectious diseases.
They represent one of the most serious burdens to public health,
afﬂicting more than 1 billion people - around one sixth of the world
population - most of which live in the poorest and the most
marginalized areas of developing countries [1].
Despite the apparent similarities, the control initiatives and
forms of treatment of NTDs are highly heterogeneous. There are
effective drugs to treat many of these diseases, available at low costes; DHODH, dihydroorotate
ydroorotate dehydrogenase;
ydrogenase in complex with
oorotate dehydrogenase in
nosomatid dihydroorotate
x: þ55 16 3602 4880.
boratory, Brazilian Center of
code 13083-970, Campinas e
nder the Elsevier OA license.or donated from pharmaceutical companies, and the control
depends on effective eradication programs [1e4]. Nevertheless,
there is still a large group of NTDs with no current treatment or
depending on old medicines, which cause serious side-effects, have
poor clinical effect, and display drug resistance [5,6].
One example of this scenario is found for the Leishmaniases,
a complex of vector-borne diseases caused by approximately 20
species of obligate intramacrophage parasitic protozoa from the
genus Leishmania. Classiﬁed as NTDs, the Leishmaniasis affect 12
millionmen, women and children in 88 countries around the world
with approximately 2 million new cases per year [7,8]. They are
manifested in a variety of clinical forms, ranging from cutaneous to
visceral leishmaniases, the latter being the most severe and which
can be fatal if left untreated. The current treatment for the leish-
maniases is mainly based on antimonial derivates of low speciﬁcity
that result in undesirable side-effects and shows susceptibility to
the development of drug resistance [9].
Although there is an urgent need for the development of better
tools to prevent, control and treat Leishmaniases, funding is a crit-
ical issue. With only 0.6% of total international development
assistance for health allocated to all NTDs, few public resources are
available in order to manage and develop new therapeutics to treat
this important disease.
Table 1
Crystallographic data.
Datasets LmDHODH-apoa LmDHODH-oro LmDHODH-fum
Wavelength (Å) 1.5418 1.427 1.427
Space group P61 P61 P61
Unit cell parameters (Å) a ¼ 143.7 a ¼ 141.2 a ¼ 140.9
c ¼ 69.8 c ¼ 68.4 c ¼ 68.3
Resolution range (Å) 28.5e2.0 46.2e2.5 35.2e1.9
Unique reﬂections 58 045 26 995 61 101
Redundancy 5.6 (5.5) 4.2 (3.9) 10.6(10.4)
Data completeness (%) 100 (100) 99.6 (99.4) 100 (100)
I/s(I) 10.5 (2.5) 18.8 (2.5) 25.1 (5.8)
Rsym
b (%) 6.4 (30.2) 8.1 (48.7) 7.9 (37.9)
Molecule per asymmetric unit 2 2 2
VM (Å3. Da1) 2.9 2.9 2.9
Solvent content (%) 58.0 57.3 57.3
Structure reﬁnement
Rwork
c (%) 16.9 17.7 16.5
Rfree
d (%) 20.0 20.4 18.2
Overall B (Å2) 23.05 25.67 19.26
RMSD bonds (Å) 0.012 0.011 0.010
RMSD angles () 2.282 2.273 2.308
Ramachandran analysise
Favored (%) 97.6 97.5 97.3
Allowed (%) 2.4 2.5 2.7
Outliers (%) 0.0 0.0 0.0
a Dataset statistics reproduced from [39].
b Rsym ¼
P jIobs - <I>j/
P
Iobs, where < I > is the mean intensity of multiple
observations of symmetry-related reﬂections.
c Rwork ¼
P
h k l jjFoj-jFcjj/PjFoj, where Fo is the observed structure factor and Fc
is the calculated structure factor.
d Rfree is the same as Rwork except calculated using 5% of the data that are not
included in any reﬁnement calculations.
e Distribution of dihedral angles in Ramachandran diagram were calculated with
MolProbity program [45].
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community in the study of themechanisms related to virulence and
pathogenesis of Leishmania which is signiﬁcantly contributing to
the discovery of new leads for diagnostics and drug development
[10e13]. Genome sequencing projects of Leishmania major [14],
Leishmania brasiliensis and Leishmania infantum [15], as well as
transcriptomics [16] and proteomics projects [17e19], are
producing data on gene expression proﬁle, protein localization,
three-dimensional structure, post-translational modiﬁcations,
therefore providing a rich source for the understanding the
evolution and biology of these pathogens.
Metabolic pathways, which have traditionally provided attrac-
tive targets for drug development, are of particular interest
[20e22]. As an example, the purine and pyrimidine nucleotide
biosynthesis, produced either by de novo biosynthetic or salvage
pathways, have already been pointed out as a promising source of
drug target candidates [23e25]. In particular, evidence garnered
from a variety of parasitic protozoa suggest that the selective
inhibition of dihydroorotate dehydrogenase, the fourth enzyme of
the de novo pyrimidine biosynthetic pathway, should be considered
as an attractive therapeutic target against Leishmaniasis [26e29].
The enzyme dihydroorotate dehydrogenase (DHODH; E.C,
1.3.3.1) is a ﬂavoenzyme that catalyzes the oxidation of (S)-dihy-
droorotate to orotate, the only redox reaction in the de novo
pyrimidine biosynthesis pathway. On the basis of sequence simi-
larity, the DHODHs are divided in two major classes, i.e., class 1 (A
and B) and class 2 [30]. This division correlates with subcellular
location of the proteins as well as their preferences for electron
acceptors. Enzymes of class 1 are dimeric, located in the cytosol and
can be found in Gram-positive bacteria, in the anaerobic yeast
Saccharomyces cerevisiae and in all trypanosomatids [26,31e33].
They share less than 20% sequence identity with the monomeric
membrane-bound enzymes of class 2, found in the mitochondria of
eukaryotes [34] and in some prokaryotes such as the Gram-
negative bacteria related to Escherichia coli [35e37]. The cyto-
plasmic enzymes utilize fumarate or NADþ to oxidize FMNH2,
whereas the membrane-bound enzymes require quinones as their
physiological oxidizing agent [38].
It is our interest to evaluate the potential of the L. major DHODH
(LmDHODH) as a drug target candidate by initially performing
a detailed functional characterization of the enzyme. In our previous
work, LmDHODH has been kinetically characterized to reduce fuma-
rate to succinate during the oxidation of FMNH2 to FMN [33]. The
reaction catalyzed by LmDHODH occurs by a Ping-Pong BieBi mech-
anismwhere the product of the ﬁrst half reaction (orotate) leaves the
active site to allow the entrance of the substrate (fumarate) for the
second half reaction. In the present work, we have moved further by
focusing the structural studies of LmDHODH. Here, we describe the
crystallographic structures of the recombinant LmDHODH crystallized
in its apo form (LmDHODH-apo) and complexed with orotate
(LmDHODH-oro) and fumarate (LmDHODH-fum) molecules.
Careful analysis of all three structures reveals that both orotate
and fumarate molecules occupy the same active site and exploit
similar interactions. Furthermore, analysis of LmDHODH structures
reveals that rearrangements in the dimeric interface have direct
inﬂuence on the conformation of the catalytic loop shedding light
on the structural role of the dimeric form to regulate the catalytic
mechanism of class 1A DHODHs. We further recognized that the
high degree of sequence and structural similarity observed among
trypanosomatid DHODH suggests that ligands designed to bind
LmDHODH can be exploited to validate DHODH as a therapeutic
target not only for Leishmaniasis, but also against other trypano-
somatid releated diseases, such as Chagas’ disease caused by Try-
panosoma cruzi and Sleeping Sickness (African trypanosomiasis)
caused by Trypanosoma brucei.2. Materials and methods
2.1. Protein crystallization and X-ray diffraction data collection
Recombinant LmDHODH was expressed in E. coli BL21(DE3)
strain and puriﬁed to homogeneity by nickel afﬁnity chromatog-
raphy as described elsewhere [33]. LmDHODH-apo crystals have
been previously obtained by the hanging and sitting drop vapor-
diffusion methods using lithium sulfate as precipitant agent and
ammonium sulfate as an additive [39]. Crystals of LmDHODH-oro
and LmDHODH-fum complexes were obtained by employing coc-
rystallization strategies. For LmDHODH-oro complex, puriﬁed
LmDHODH protein solution was initially dialyzed against 50 mM
Hepes pH 7.2 and 150 mM NaCl in presence of 1 mM orotate, and
concentrated up to 9.4 mg/mL. For LmDHODH-fum complex, the
puriﬁed LmDHODH protein solution has been dialyzed against
50 mM Hepes pH 7.2 and 150 mM NaCl, concentrated up to 4 mg/
mL and incubated for 3 h with 5 mM fumarate. Cocrystallization
experiments were performed at 293 K by using the sitting drop
vapor-diffusion method. Drops were prepared by mixing 2.0 mL of
protein solution and 2.0 mL of reservoir solution containing
1.2e1.3 M lithium sulfate, 0.3e0.35 M ammonium sulfate in 0.1 M
sodium citrate tribasic dihydrate pH ¼ 5.3e5.6.
Prior to X-ray data collection, the crystals were transferred to
a cryoprotectant solution comprising reservoir solution supple-
mented with 20% glycerol, and ﬂash-cooled in a nitrogen stream.
Data collection for LmDHODH-apo was performed using an in-
house rotating-anode generator [39]. For both LmDHODH-oro and
LmDHODH-fum complexes, the data collections were performed at
the protein crystallography beamline D03B-MX1 of the Brazilian
Synchrotron Light Laboratory (LNLS) using X-rays of wavelength
1.427 Å radiation and recorded on a marCCD165 detector. All three
X-ray data sets were collected at 100 K. Diffraction data were
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SCALA [41]. Table 1 summarizes data collections statistics.
2.2. Phasing and reﬁnement
The structure of LmDHODH-apo was solved by molecular replace-
ment using the coordinates (excluding the water molecules) of the
dimeric structure of Lactococcus lactis DHODH as the search model
(PDB code: 1DOR [42]). Crystals of the two complexes LmDHODH-oro
and LmDHODH-fum proved to be isomorphous to LmDHODH-apo
crystal previously obtained in the space group P61. Thus, the coordi-
nates of the LmDHODH-apowithwaters removedwere used to obtain
an initial set of phases for both LmDHODH-oro and LmDHODH-fum
complexes. The coordinates for the orotate and fumarate molecules
and appropriate chemical restraints and topology ﬁles were prepared
using Hetero-compound Information Center - Uppsala (HIC-Up)
server. Waters were built using Coot [43] and validated by hand. The
models were initially reﬁned by rigid body reﬁnement, followed by
several rounds of model rebuilding using Coot and reﬁnement with
REFMAC5 [44]. Table 1 summarizes reﬁnement statistics. The stereo-
chemistry for LmDHODH-apo, LmDHODH-oro and LmDHODH-fum
models were validated with Molprobity [45]. All pictures were
generated with the PYMOL software [46].
2.2.1. Protein data bank accession codes
Coordinates and structure factors have been deposited in the
PDB with the accession codes 3GYE (LmDHODH-apo), 3GZ3
(LmDHODH-oro), and 3TQ0 (LmDHODH-fum).Fig. 1. Stereoscopic ribbon representation of Leishmania major DHODH. Top, LmDHODH mon
magenta is surrounded by eight a-helices (a1- a8) illustrated in yellow. Two N-terminal an
secondary structural elements and loops form a protuberant subdomain present at the top o
salmon. Stick representation of the prosthetic FMN group is illustrated in yellow. Bottom,
references to color in this ﬁgure legend, the reader is referred to the web version of this ar3. Results and discussion
3.1. Structure determination
Crystallization, X-ray diffraction data acquisition and initial
phasing of LmDHODH in its apo form (LmDHODH-apo) was previ-
ously described [39]. LmDHODH-apo crystallized in P61 space
group using lithium sulfate as the precipitant agent and its crystal
structure was solved by molecular replacement using the crystal-
lographic structure of L. lactis DHODH as the search model [42]. A
complete dataset to 2.0 Å resolution was used to reﬁne the
LmDHODH-apo structure, which consisted of a dimer in the
asymmetric unit. Both polypeptide chains (chains A and B)
comprises residues from Met1 to Leu129 and Asp143 to Leu312, and
bind non-covalently to one FMN molecule. Residues from Ser130 to
Tyr142 and eight C-terminal residues (Asp313 to Arg320) were
excluded from the ﬁnal structure due to the lack of interpretable
electron density. The ﬁnal LmDHODH-apo model contains two
polypeptide chains, two FMN and two glycerol molecules and 358
solvent sites treated as water oxygens.
Crystals of LmDHODH-oro and LmDHODH-fum complexes were
obtained by cocrystallization techniques. LmDHODH-oro and
LmDHODH-fum crystals displayed a high degree of isomorphism
related to the LmDHODH-apo, with the same hexagonal symmetry
and cell parameter deviation lower than 1%. The reﬁned coordi-
nates of LmDHODH-apo (excluding the solvent molecules) were
used for initial rigid body reﬁnement of LmDHODH-oro and
LmDHODH-fum structures at 2.5 and 1.9 Å resolution, respectively.omer where a central barrel composed of eight parallel b strands (b1- b8) illustrated in
tiparallel b strands (ba-bb) are found at the bottom of the barrel (red) and additional
f the barrel (green, aquamarine and orange). Active site loop (b4- a4 loop) is shown in
the native functional dimer found in the asymmetric unit. (For interpretation of the
ticle.)
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composed by the same group of residues as found for LmDHODH-
apo, where the segments from Ser130 to Tyr142 and Asp313 to Arg320
with no interpretable electron density were excluded from
LmDHODH-oro ﬁnal coordinates. The ﬁnal structure contains two
polypeptide chains, two FMN, two orotate and two glycerol mole-
cules, and 430 solvent sites treated as water oxygens.
The polypeptide chains of LmDHODH-fum crystallographic
model comprises residues ranging from Ser0 (a plasmid-encoded
residue that precedes Met1) to Leu312. The C-terminal residues
ranging from Asp313 to Arg320 were also not included in the ﬁnal
coordinates due to the lack of electron density. Contrary to the
LmDHODH-apo and LmDHODH-oro models, residues Ser130 to
Tyr142 of LmDHODH-fum were observed in an ordered state with
mean Bfactor value equal to 18.3 (chain A) and 19.1 (chain B) Å2. The
ﬁnal structure contains two polypeptide chains, two FMN, two
fumarate, two glycerol molecules, one nickel atom, four sulfate
ions, and 388 solvent sites treated as water oxygens.
Final reﬁnement and geometry statistics for all three structures
are detailed in Table 1.3.2. Overall structures
LmDHODH monomer shows the typical a/b barrel fold of class
1A DHODH, with a central barrel composed of eight parallel
b strands (b1- b8) surrounded by eight a-helices (a1-a8) (Fig. 1). Two
N-terminal antiparallel b strands (ba-bb) are found at the bottom of
the barrel, whereas additional secondary structural elements and
loops, including a conserved four-stranded antiparallel b-sheet (bc,
bd, be and bf), form a protuberant subdomain present at the top of
the barrel. The prosthetic FMN group is located between the top of
the barrel and the subdomain formed by these insertions.
The dimeric structure of LmDHODH is very similar to all avail-
able models for class 1A DHODHs (Fig. 1): L. lactis DHODH
(LlDHODH, PDB code: 2DOR [47],), T. brucei DHODH (TbDHODH,
PDB code: 2B4G [27],), Leishmania donovani DHODH (LdDHODH,
PDB code: 3C61, results not published), T. cruzi (Y strain) DHODH
(TcDHODH_Y, PDB code: 3C3N [48],) and T. cruzi (Tulahuen strain)
DHODH (TcDHODH_T, PDB codes: 2E68, 2E6A, 2E6D, 2E6F, 2DJL and
2DJX [49];) and Streptococcus mutans (StmDHODH, PDB code: 3OIX
[50];). The superposition of Ca atoms between LmDHODH-apo and
the structurally equivalent atoms show on average (chain A) a rmsd
of 0.20 Å for LmDHODH-oro, 0.37 Å for LmDHODH-fum, 0.28 Å for
LdDHODH, 0.46 Å for TbDHODH, 0.61 Å for TcDHODH_Y, 0.59 Å for
TcDHODH_T, 1.01 for StmDHODH and 0.91 Å for LlDHODH; values
very similar to the Ca rmsd of 0.22 Å found when we superposeFig. 2. sA-weighted 2Fo-Fc electron density maps countered at 1.5 s level (where s is thchains A and B in the asymmetric unit in LmDHODH-apo structure.
Analysis of rmsd distribution for each residue along the protein
sequence suggest a conserved structural pattern for the a/b barrel
found in class 1 DHODH structures. The largest differences are
found at the N- and C-terminal regions, from Leu129 to Tyr142, from
Phe144 to Val157 and from Val202 to Pro214. Our ﬁndings are in
agreement with the sequence variability and intrinsic ﬂexibility of
those regions. In particular residues found from Leu129 to Tyr142 are
part of the catalytic loop, where the mobility is related to its ability
for controlling the access and release of substrate from the active
site [51].3.3. Binding mode of orotate and fumarate molecules
Orotate and fumarate molecules correspond to the product of
catalysis and the oxidant agent for class 1A DHODHs, respectively.
Both molecules were clearly present in the active site, as observed
by the ﬁnal sA-weighted 2Fo-Fc maps for the corresponding
complexes (Fig. 2).
Both orotate and fumaratemolecules were found approximately
parallel to the isoalloxazine ring. In detail, the pairs of orotate
atoms (N1)/(O2) and (N3)/(O4) make bidentate hydrogen bonds to
(Od1)/(Nd2) side chain atoms of Asn68 and Asn195, respectively.
Orotate (N1), Asn68 (O) and (Od1) atoms are also hydrogen bonded
to a solvent molecule (O2) and (O4) orotate atoms are involved in
additional hydrogen bonds with (Og) from Ser196 and (Nd2) atoms
from Asn128 and Asn195. One orotate carboxylate oxygen atom
(O71) participates as an acceptor in hydrogen bonds with Lys44 (Nz)
and Leu72 (N) atoms. The second orotate carboxylate oxygen (O72)
is also the acceptor in hydrogen bonds with Gly71 (N) andMet70 (N)
atoms. Additionally, O72 is also hydrogen bonded to a solvent
molecule. Both waters involved in hydrogen bonds with orotate in
the active site of chain A are matched by equivalent water mole-
cules interacting with the orotate molecule associated to chain B.
Similarly, the pair of atoms O4A/O4B from fumarate participates
in a bidentate hydrogen bond to Nd2/Od1 from Asn195, additionally
(O4A) makes a second hydrogen bond to Asn128 (Nd2) (Fig. 3).
Fumarate (O1B) atom makes hydrogen bond to Leu72 (N) and Lys44
(Nz), while (O1A) makes hydrogen bound to Gly71 (N). Fumarate
(O1A) establishes a hydrogen bond to Asn133 (Nd2) located in the
active site loop. Additionally, Asn133 makes hydrogen bonds via its
main chain (O) and side chain (Nd2) atoms to Asn54 (Nd2) and Asn68
(Od1). Interactions involving Asn133 are not observed in either the
LmDHODH-apo or the LmDHODH-oro because of the disordered
state of their active site loops. In LmDHODH-fum, a water molecule
occupies the equivalent position of orotate (O2) atom ine root mean square value of the electron density) for orotate (A) and fumarate (B).
Fig. 3. Stereoscopic three-dimensional representation of the LmDHODH active site showing the superposition of orotate (pink) and fumarate (green) complexes. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
A.T. Cordeiro et al. / Biochimie 94 (2012) 1739e1748 1743LmDHODH-oro, and interacts via hydrogen bonds with fumarate
(O4B), Asn133 (Nd2), Asn68 (Nd2) and Ser196 (Og) (Fig. 4). The latter
two interactions are equivalent to the hydrogen bonds between
orotate (O2) and Asn68 (Nd2) and Ser196 (Og) from LmDHODH-oro.
Cys131 which has been previously described to be the catalytic
base for class 1A DHODH [30,49] and is responsible for abstracting
a proton from the substrate dihydroorotate (C5) is not present in
the LmDHODH-apo and LmDHODH-oro due to the lack of inter-
pretable electron density. In the LmDHODH-fum structure, where
the catalytic loop is stabilized, the Cys131 is located with its Sg at
distances 3.6 Å, 4.2 Å and 4.3 Å from fumarate C3, C4 and O1A,
respectively.
Overall, the global structures of the protein molecules in the two
cocrystal structures are almost identical. Nevertheless, a notable
difference is observed in LmDHODH-fum structure where the active-
site loop is found in a closed conformation. Different fromFig. 4. Stereoscopic drawing of the dimer interface in LmDHODH structure. In LmDHODH
Interactions involved in nickel binding are represented in dashed black lines A water mole
His174, Phe170 and Tyr142 (light blue). The presence of a nickel ion in this cavity induces a
structure (green). (For interpretation of the references to color in this ﬁgure legend, the reLmDHODH-apo and LmDHODH-oro structures where the same region
is found disordered, this observation could initially suggest that only
fumarate could stabilize the active-site loop in its closed conformation.
However, inspection of several crystal structures available for class 1A
DHODH in the apo form (1DOR [42], 2DJX [49], 3OIX [50], LmDHODH-
apo); in complex to orotate (2DOR [47], 2E6A [49], 3C61 [data not
published], 2B4G [27], LmDHODH-oro); in complex to fumarate (2E6D
[49], LmDHODH-fum) or even in complex to different ligands (2BSL,
2BX7 [52], 3C3N [48], 2E68, 2E6F, 2DJL [49], 3MJY and 3MHU [53])
supports the observation that the position of the catalytic loop
described for class 1A crystal structures does not intrinsically depend
on the occupancy of the active site. For example, in the apo structures
the loop is found stabilized in the closed position for 1DOR and 2DJX,
whereas for 3OIX the same region is found stabilized in an open
conformation and for LmDHODH-apo is found disordered. For
DHODH-orotate complexes the loop is commonly found stabilized in-fum structure a nickel ion is found at the dimer interface with double occupancy.
cule (orange) mediates the interaction of nickel ion (purple) and the protein residues:
shift in both His174 and Asp171 conformations when compared to the LmDHODH-apo
ader is referred to the web version of this article.)
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region is found disordered. In general, we observe that the different
conformations adoptedby the active-site loop in LmDHODHstructures
is favored by the crystal form, where the active site loop is solvent-
exposed allowing us to capture different conformations. This is very
different, for example, from T. cruzi strain Y DHODH [48] and T. brucei
DHODH[27] crystal structureswhere forcesof crystal packingalsoplay
an important role in stabilizing the conformationof theactive site loop.
Noteworthy, analysis of class 1A DHODH-inhibitor complexes
reveals that not only the catalytic loop can adopt both the closed
conformation (2BSL and 2BX7) and a disordered state (3MJY and
3MHU), but also that the length of the disordered region may vary.
For example, compared to LmDHODH-apo and LmDHODH-oro
where the ﬂexible region comprises residues from Ser130 to Tyr142,
the disordered region for LmDHODH in complex with orotate
analogs, 5-aminoorotic acid (3MJY) and 5-nitroorotic acid (3MHU),
is shorter and comprises residues from Cys131 to Pro138 and from
Pro132 to Pro138, respectively. The shortened disordered regions
found in 3MJY and 3MHU structures are consequence of direct
interactions between the ligands and the base of the catalytic loop,
suggesting that class 1A inhibitors can explore fumarate and oro-
tate interactions in the active site in order to enhance selectivity
and also interfere with loop ﬂexibility to increase potency.
In summary, the three-dimensional structures of LmDHODH-oro
and LmDHODH-fum, where orotate and fumarate are found to bind
to the same active site, are consistent with the previous kinetic
characterization which showed that catalysis of LmDHODH is per-
formed by a Ping-Pong BieBi mechanism [32].
3.4. Dimer interface
LmDHODH exists as homodimer both in solution [33] and in the
asymmetric unit. The two monomers of LmDHODH are related by
a non-crystallographic 2-fold axis with forty-six amino acid resi-
dues from each subunit stabilizing the dimer interface. Hydro-
phobic, hydrophilic and, in particular, stacking interactions play an
important role in dimer stability. P-stacking interactions are found
between Phe170 (chain A) and Phe170 (chain B), Phe218 (chain A) and
Phe172 (chain B), Phe218 (chain B) and Phe172 (chain A) and a cation-
p interaction is found between Lys215 and Phe172.Fig. 5. Stereoscopic drawing of the molecular surface in LmDHODH structure. The sites S1, S
(B) indicates chain A (white) and B (light gray). A ribbon representation (in black) indicates
S3 and S5 sites. (For interpretation of the references to colour in this ﬁgure legend, the reaThe great majority of residues found at the interface: Pro57,
Leu64, Pro138, Gln139, Phe170, Asp171, Phe175, Gly198, Asn199, Gly200,
Leu201,Ile203, Glu208, Val210, Val211, Lys213,Lys215, Phe218, Tyr225,
Pro228, Thr229, Leu231, Ala232, Leu263 Lys297,Tyr299 are completely
conserved within class 1A DHODHs. In addition, conservative
substitutions are found at positions Ile197, Glu206, Ser209, Ile212,
Leu221, Asn235 and Arg310. This high degree of sequence conserva-
tion sheds light on a potential functional role for the dimeric form
in class 1A DHODHs. Actually, the relevance of the dimeric form for
class 1A DHODH has been previously reported [54]. In their studies,
Ottosen and collaborators showed that a dimer dissociation
induced by site directed mutagenesis led to the loss of enzymatic
activity in L. lactis DHODH. Furthermore, single-molecule studies
previously reported have provided evidences for half-sites reac-
tivity in class 1A DHODH, inwhich only one subunit reacts at a time
[55]. In this present model, the dimeric interface could also play an
important role in the exchange of information between the two
subunits during catalysis.
Interestingly, when the catalytic loop is found stabilized, as only
observed in LmDHODH-fum structure, a cavity (200 Å3) surrounded
by the fully conserved residues Phe170, His174, Tyr169 and Tyr142 is
formed at the dimer interface (Video 1). During crystallographic
reﬁnement of LmDHODH-fum complex, analysis of sA-weighted
2Fo-Fc and Fo-Fc maps indicated the existence of a strong electron
density in this cavity. A careful inspection of the 1.9 Å resolution
map revealed that a speciﬁc atom tightly interacts with neighbor
residues and water molecules within this cavity.
Supplementary video related to this article can be found at doi:
10.1016/j.biochi.2012.04.003
To further investigate the character of this atom, we estimated the
atomic occupancies and temperature factor for different atomspresent
in the buffers used for protein puriﬁcation and crystallization. Water
molecules, alkali metal cations: Naþ, Kþ, Liþ, divalent cations: Ca2þ,
Ni2þ and the monovalent ions Cl and NH4þ, were evaluated to ﬁt and
satisfy both chemical and electron density requirements. Our strategy
shows that the binding species are most likely to be Ni2þ (present
during protein puriﬁcation), although we cannot completely rule out
the possibility of coexistence of other species with lower occupancies.
As a consequence of the 2-fold axis of the dimer, the Ni2þ ion has
been found to occupy this cavity with double occupancy (Fig. 4) and2, S3, S4 and S5 are indicated by pink, blue, orange, green and red, respectively (A) and
the position of the catalytic loop in both subunits and which involves residues from S2,
der is referred to the web version of this article.)
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cules and protein residues from both subunits. A water molecule is
found to mediate an interaction between each Ni2þ ion (OeNi
distance of 2.5 Å) and both Phe170 (OeN distance of 2.8 Å) and
His174 (O-Nd1 distance of 2.6 Å) residues (Fig. 4). In addition, the
position of the divalent cation is stabilized by the aromaticp-system
of Tyr142, as a further evidence of the chemical nature of our ligand.
A comparison among LmDHODH-apo, LmDHODH-oro and
LmDHODH-fum structures indicates that a conformational change
in both His174 and Asp171 side chains and a consequent disruption of
a hydrogen bond between those two residues can be observed
when the divalent cation is found in the dimer interface (Fig. 4).
The range of interactions observed in the LmDHODH-fum
complex, are present neither in LmDHODH-apo nor LmDHODH-oro
crystal structures, as a consequence of the high ﬂexibility observed
for the catalytic loop. Actually, it can be observed that the move-
ment of the region comprising from Leu129 to Tyr142 and required
for regulating catalysis has a direct inﬂuence on the dimeric
interface, resulting in dynamic changes in the volume and charge
distribution of the cavity where the cation ion has been found.
Furthermore, our ﬁndings support the observation that theFig. 6. Sequence alignment of trypanosomatid DHODHs: LmDHODH (Leishmania major), LiDH
mexicana), LbrDHODH (Leishmania braziliensis), TbDHODH (Trypanosoma brucei), TcDHODH
TcDHODH-Tulahuen1 (T. cruzi strain Tulahuen). The sites S1, S2, S3, S4 and S5 are indicated
using MULTALIN [57] and graphically displayed using ESPript [58]. (For interpretation of the r
article.)stabilization of the catalytic loop does not depend on the occupancy
of the active site.
Analysis of 19 class 1A DHODH structures available at the
Protein Data Bank reveals that this binding pocket at the dimer
interface is always occupied by ligands of different volume and
chemical properties. Water molecules are usually found, as
observed in the structures of LmDHODH-apo and LmDHODH-oro
complexes. Glycerol molecules in different orientations and a DTT
molecule have also beenmodeled in the electron density found this
cavity (PDB IDs 3OIX, 1JUE, 2BSL, 2BX7, 3C3N and 3C61). In one
particular case, analysis of the high resolution data available for the
crystal structure of T. cruzi DHODH in complex to oxonate (PDB ID
2E6F [49],) allowed us to unambiguously assign a PEG molecule for
remaining electron density found at the dimer interface (supple-
mental Fig. S1). Furthermore, the ﬁnal sA-weighted 2Fo-Fc and Fo-Fc
maps for the available structures frequently show remaining
spurious density in this region accounting for either low occupancy
or high ﬂexible molecules. This promiscuous nature of this binding
pocket could be interpreted as a result of extensive hydrophobic
contacts as well as a network of polar interactions available on the
periphery of the protein surface.ODH (Leishmania infantum) LdDHODH (Leishmania donovani), LmxDHODH (Leishmania
-Y (Trypanosoma cruzi strain Y), TcDHODH-CLBrener1 (T. cruzi strain CLBrener) and
by pink, blue, orange, green and red stars, respectively. The alignment was performed
eferences to colour in this ﬁgure legend, the reader is referred to the web version of this
A.T. Cordeiro et al. / Biochimie 94 (2012) 1739e17481746To date there is no evidence supporting the need of a cation ion
or any ligand for the stabilization the dimeric form or for regulating
the catalytic activity in class 1A DHODHs. However, as observed in
this work, there is a structural relationship between the dimer
interface and the conformation of the catalytic loop, suggesting that
the binding of speciﬁc molecules at the oligomer interface may
alter the catalytic properties of class 1A DHODH.
Thus, considering the relevance of the oligomerization state for
class 1A DHODH activity [54,55], together with the absence of the
dimeric interface in class 2 DHODHs, it is of our interest to exploit
this binding site for the design of class 1A DHODH selective
inhibitors. Site-directedmutagenesis studies are now in progress in
order to provide the molecular basis that correlates the dimer
interface and protein function.
3.5. Trypanosomatid DHODHs and implications for inhibitor design
The genome sequencing projects of trypanosomatid organisms,
which include human pathogenic species like T. cruzi [56], T. brucei
[20] and Leishmania species [14,15] have had amajor contribution in
the characterization of several genes involved in the parasites’
biology. Also, they have allowed the identiﬁcation of similarities
and differences at molecular level of these related species. To date,
the genome annotation process has assigned the putative function
for DHODH enzyme to gene products of different trypanosomatids
and reveals a high degree of sequence identity varying from 73 to
76% when comparing LmDHODH to homologous trypanosoma
DHODHs and 83e96% when compared to other Leishmania species
(Fig. 6). Trypanosomatid DHODH (TrypDHODHs) share around
50e57% of sequence identity when comparing to other members of
class 1A DHODHs and 18e27% when comparing to members of
class 2 DHODH. In particular, LmDHODH and the homologous
human enzyme (HsDHODH) share approximately 25% of sequence
identity.
According to our previous work, there are signiﬁcant differences
between TrypDHODHs and the homologous human enzyme that
could guide the selection of target sites for drug discovery [48]. By
using TcDHODH as a model, topological analysis helped us to
identify ﬁve different independent regions that display appropriate
shape, volume and location to interact with ligands and thus could
be exploited for the design of selective ligands against TrypDHODHs
[53]. Named according to the distance from the active site, these
sites comprise: the active site (S1); an extension of S1 site (S2); the
site behind the catalytic loop (S3); an extension of S3 site (S4); and
the cavity found at the dimeric interface (S5) (Fig. 5). Careful
analyses of the crystal structures of LmDHODH-apo and
LmDHODH-oro described in this work which reveals the lack of
electron density from Leu129 to Tyr142 have allowed us to estimate
the length of the ﬂexible region of the active site loop (b4- aA loop;
Fig. 5). In addition, the monitoring of the conformation dynamics of
the active site loop, which comprises residues from S2, S3 and S5
sites (Fig. 5), has brought to our attention the plastic character of S2
to S5 pockets of interaction, as well as the different possible routes
of accessing the active site, suggesting new possible strategies to be
exploited in the design of TrypDHODHs inhibitors.
When comparing LmDHODH against all available TrypDHODHs
sequences and structures, we found that all sites (S1 to S5) are
highly conserved in terms of conformation and chemical nature
(Fig. 6). S1, S3 and S5 sites are found fully conserved and only few
substitutions are found at S4 and S2 sites, the later recently vali-
dated as a new site of interaction for inhibitor development against
class 1A DHODHs [53]. At the S4 site a single mutation can be
observed in Leishmania species where the conserved Ile172 found in
T. cruzi and T. brucei DHODHs is replaced by a Phe172 (Fig. 6). As
a result, S4 site is found to be slightly shallower in Leishmaniastructures. At the S2 site a highly conserved Leu102 is replaced by
Phe102 in L. brasiliensis DHODH and Asn107 is replaced by Ser107 in
T. brucei DHODH. Despite those few substitutions, the proﬁle of
interactions for molecular recognition is kept conserved at S2 and
S4 binding cavities within TrypDHODHs.
The only point mutation that deserves special attention is at
Tyr150 which is found replaced by Cys150 in the majority of Leish-
mania species with exception of Leishmania braziliensis (Fig. 6). The
differences in volume, geometry of its side chain at the S2 site and
the highly reactive character of this free cysteine residue could
drive an alternative route for the design of selective inhibitors
covering a large spectrum of Leishmania DHODHs.
4. Conclusion
We report the determination of the crystal structure of
LmDHODH in its apo form and in complex with both orotate and
fumaratemolecules. Our ﬁndings provide a new contribution to the
understanding of the mechanism of action of class 1A DHODHs and
for the structure-assisted design of inhibitors against LmDHODH.
Furthermore, the high sequence and structural similarities
observed among trypanosomal DHODHs associated to the intrinsic
differences between class 1 and class 2 DHODHs suggests that
a single strategy can be used for the development of selective
DHODH inhibitors that target multiple trypanosomatid targets.
Work is ongoing to validate DHODH as druggable target for
multiple neglected tropical diseases such as Leishmaniasis,
Sleeping Sickness and Chagas’ Diseases.
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